All‐cause death · children
RotaTeq showed no clear difference in all‐cause death compared with placebo (low certainty).
3 findings from 1 review
RR 1.24 [0.69, 2.22]
6 studies · 72654 participants
Low
RR 0.33 [0.01, 8.18]
2 studies · 4088 participants
Very low
RR 0.91 [0.68, 1.23]
3 studies · 7706 participants
Moderate
All serious adverse events · children
RotaTeq showed no clear difference in all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.92 [0.84, 1.01]
5 studies · 70690 participants
High
RR 0.66 [0.14, 3.17]
2 studies · 4082 participants
Very low
RR 0.99 [0.72, 1.36]
4 studies · 7730 participants
Moderate
Serious adverse events: intussusception · children
RotaTeq showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
3 findings from 1 review
RR 0.69 [0.35, 1.38]
9 studies · 73925 participants
Low
RR 5.01 [0.24, 104.29]
2 studies · 4082 participants
Very low
RR 0.33 [0.01, 8.16]
2 studies · 7488 participants
Low
Severe cases of rotavirus diarrhoea · children
Rotasiil leads to lower severe cases of rotavirus diarrhoea compared with placebo (high certainty).
2 findings from 1 review
Severe cases of all‐cause diarrhoea · children
Rotasiil showed no clear difference in severe cases of all‐cause diarrhoea compared with placebo (high certainty).
2 findings from 1 review
All‐cause death · children
Rotasiil showed no clear difference in all‐cause death compared with placebo (moderate certainty).
1 finding from 1 review
All serious adverse events · children
Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events: intussusception · children
Rotasiil showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
1 finding from 1 review
Severe cases of rotavirus diarrhoea · children
Rotavac probably leads to lower severe cases of rotavirus diarrhoea compared with placebo (moderate certainty).
2 findings from 1 review
Severe cases of all‐cause diarrhoea · children
Rotavac probably leads to lower severe cases of all‐cause diarrhoea compared with placebo (moderate certainty).
2 findings from 1 review
All‐cause death · children
It is very uncertain whether rotavac changes all‐cause death compared with placebo (very low certainty).
1 finding from 1 review
All serious adverse events · children
Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: intussusception · children
It is very uncertain whether rotavac changes serious adverse events: intussusception compared with placebo (very low certainty).
1 finding from 1 review
Response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) compared with placebo (very low certainty).
1 finding from 1 review
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Speed of onset of response · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall adverse events 5 weeks · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes overall adverse events 5 weeks compared with placebo (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · women undergoing assisted reproduction
Dopamine agonist probably leads to lower incidence of moderate or severe OHSS compared with placebo/no intervention (moderate certainty).
1 finding from 1 review